MC1R Variants, TERT Mutations, and Melanoma Prognosis: A Study Timeline
Cutaneous melanoma presents complex clinical challenges, particularly when tumors penetrate deeper into the skin layers. Even after surgeons successfully perform a complete surgical excision, stage IIB and stage IIC cutaneous melanomas carry a substantial risk of disease recurrence and patient mortality. Because of this persistent threat, medical researchers continue investigating biological markers to better predict which patients face a higher likelihood of disease progression.
The Clinical Challenge of Stage IIB and IIC Melanoma
In the landscape of cutaneous melanoma, tumors classified as stage IIB and IIC represent thicker primary lesions that have not yet demonstrated distant spread at initial diagnosis, yet they harbor an elevated risk of returning. Standard treatment relies on complete surgical removal of the tumor, but surgery alone does not eliminate the possibility of microscopic persistence or future relapse. Clinical teams therefore rely on prognostic biomarkers to help clarify long-term risk profiles.
To identify clearer patterns, researchers have increasingly evaluated interactions between inherited genetic traits and mutations that emerge within tumor tissue. A 2026 paper published in the journal Melanoma Research, titled Melanocortin-1 receptor variants and telomerase reverse transcriptase promoter mutations as prognostic biomarkers in stage IIB-IIC melanoma, investigated whether combining germline and somatic markers could refine prognostic assessments.
The Research Timeline: May 2000 to August 2024
Understanding cancer outcomes often requires tracking patients across substantial periods. In this single-center investigation, clinicians and scientists retrospectively analyzed 153 patients with stage IIB-IIC cutaneous melanoma who underwent surgical resection at the Instituto Valenciano de Oncología. The timeline of clinical care and surgical interventions spanned more than two decades, beginning in May 2000 and running through August 2024.
Over the course of the investigation, researchers followed the cohort for an extensive period, recording a median follow-up time of 81.6 months. This extended observation allowed the investigators to track three primary endpoints using Kaplan-Meier survival curves:
- Recurrence-free survival (RFS): The median duration across the patient group was 43 months.
- Disease-free survival (DFS): The median duration reached 31 months.
- Overall survival (OS): The median duration was recorded at 50 months.
Divergent Roles of MC1R Variants and TERT Promoter Mutations
The core objective of the Melanoma Research study was to assess two specific genetic components: inherited variants in the melanocortin-1 receptor gene and acquired mutations in the telomerase reverse transcriptase (TERT) promoter within tumor tissue. The melanocortin system is well known for directing baseline skin pigmentation pathways, as detailed in our guide to MC1R and skin pigment, but its broader biological influence continues to be analyzed in clinical oncology.
Statistical evaluations using log-rank tests and Cox proportional hazards models revealed contrasting behaviors between these two markers:
- Univariate RFS findings: Both TERT promoter mutations (hazard ratio = 0.38, 95% confidence interval [CI] = 0.18-0.8, P = 0.008) and the absence of MC1R variants (hazard ratio = 0.38, 95% CI = 0.16-0.91, P = 0.024) demonstrated significant associations with recurrence-free survival.
- Multivariate RFS findings: When adjusting for multiple variables, only TERT promoter mutations maintained status as an independent predictor of recurrence-free survival (hazard ratio = 0.44, 95% CI = 0.20-0.96, P = 0.038).
- Multivariate DFS findings: TERT promoter mutations also served as an independent predictor for disease-free survival in multivariate testing (hazard ratio = 0.47, 95% CI = 0.24-0.93, P = 0.030).
Ultimately, patients harboring TERT promoter mutations exhibited significantly poorer survival outcomes when compared with individuals with wild-type TERT promoter status. Furthermore, combined molecular analyses supported contrasting prognostic roles for these elements, leading the authors to suggest a potential protective role associated with MC1R variants in stage IIB-IIC melanoma.
Study Design Limits and What Readers Should Keep in Mind
While these findings provide intriguing insights into melanoma biology, the results must be viewed within the boundaries of the study design. This was a retrospective, observational study conducted at a single medical institution involving 153 patients. Retrospective reviews inherently carry limitations compared to prospective clinical trials, and findings from one specific hospital cohort cannot automatically be generalized to all patient populations or earlier-stage tumors.
Additionally, members of the public researching melanocortin receptors should avoid confusing basic biological receptor studies with commercial products. Injectable peptides such as melanotan I or melanotan II sold over the internet are unapproved, unregulated drugs that have not undergone clinical review for safety or efficacy. Anyone concerned about personal skin cancer risks, abnormal lesions, or melanoma prognosis should consult a board-certified dermatologist or oncologist for professional medical advice.
Sources
Published October 28, 2026. Sources are linked in the text. See our Medical Disclaimer.